Literature DB >> 10190423

Double external direct-current shocks for refractory atrial fibrillation.

P Bjerregaard1, A El-Shafei, D L Janosik, L Schiller, A Quattromani.   

Abstract

Encouraged by preliminary data using double external direct-current (DC) shocks in patients with atrial fibrillation refractory to single external DC shocks, we undertook a prospective study of all patients with atrial fibrillation of > 1-month duration using a shock sequence with (1) 1 shock of 200 J anterior-posterior, (2) 1 shock of 360 J anterior-posterior, (3) 1 shock of 360 J apex-anterior, and (4) double shocks with configurations 2 and 3 delivered almost simultaneously by 2 defibrillators. The double shocks appeared to be safe and restored sinus rhythm in approximately 2 of 3 of patients in whom DC cardioversion failed with single shocks.

Entities:  

Mesh:

Year:  1999        PMID: 10190423     DOI: 10.1016/s0002-9149(98)01048-0

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  4 in total

1.  Successful external cardioversion of atrial fibrillation in patients referred to an electrophysiologist for internal cardioversion.

Authors:  R J Verdino; J J Teuteberg; M C Burke; D E Kopp; C T Johnson; A C Lin; M Alberts; J G Kall; D J Wilber
Journal:  Clin Cardiol       Date:  2001-07       Impact factor: 2.882

2.  Higher energy monophasic DC cardioversion for persistent atrial fibrillation: is it time to start at 360 joules?

Authors:  C Boos; M D Thomas; A Jones; E Clarke; G Wilbourne; R S More
Journal:  Ann Noninvasive Electrocardiol       Date:  2003-04       Impact factor: 1.468

3.  Orthogonal electrical cardioversion in atrial fibrillation refractory to biphasic shocks: a case series.

Authors:  Enrique Velázquez-Rodríguez; Hipólito Alfredo Pérez-Sandoval; Francisco Javier Rangel-Rojo
Journal:  Eur Heart J Case Rep       Date:  2020-11-14

Review 4.  Postoperative arrhythmias after cardiac surgery: incidence, risk factors, and therapeutic management.

Authors:  Giovanni Peretto; Alessandro Durante; Luca Rosario Limite; Domenico Cianflone
Journal:  Cardiol Res Pract       Date:  2014-01-06       Impact factor: 1.866

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.